Characterizing intermediate-risk non–muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy

Abstract Purpose Patients with intermediate-risk non–muscle-invasive bladder cancer have traditionally been defined as those not included in the low- or high-risk groups. Therefore, the intermediate-risk group consists of heterogeneous patients. Materials and methods We reviewed 326 patients diagnos...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2017-05, Vol.35 (5), p.208-214
Main Authors: Matsumoto, Kazuhiro, M.D, Kikuchi, Eiji, M.D., Ph.D, Yanai, Yoshinori, M.D, Hayakawa, Nozomi, M.D, Ito, Yujiro, M.D., Ph.D, Maeda, Takahiro, M.D, Nagata, Hirohiko, M.D, Miyajima, Akira, M.D., Ph.D, Oya, Mototsugu, M.D., Ph.D
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Bacillus Calmette-Guérin
BCG
BCG Vaccine - therapeutic use
Chemotherapy, Adjuvant
Disease Progression
Disease-Free Survival
Female
Humans
Intermediate risk
Male
Middle Aged
Neoplasm Invasiveness
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - surgery
Non–muscle-invasive bladder cancer
Risk Assessment
Risk Factors
Urinary Bladder Neoplasms - classification
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - surgery
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Purpose Patients with intermediate-risk non–muscle-invasive bladder cancer have traditionally been defined as those not included in the low- or high-risk groups. Therefore, the intermediate-risk group consists of heterogeneous patients. Materials and methods We reviewed 326 patients diagnosed with intermediate-risk tumors. We subclassified these patients into 3 groups according to their clinical courses. Group A included patients with initial and multiple low-grade tumors ( N = 170). Group B consisted of patients with a low-grade tumor that recurred after a low-risk tumor ( N = 97), and Group C consisted of patients with a low-grade tumor that recurred after a high-risk tumor ( N = 59). Results The 2-year recurrence-free survival rate was significantly lower in Group C (42%) than in Groups A (69%, P
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2016.11.014